PBS, 1% BSA, 0.3% Proclin 300
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
| 应用 | 稀释度 | 推荐种属 |
|---|---|---|
| FCM | 1.25μl per million cells in 100μl volume | Hu |
HLA-DR is a subtype of the human leukocyte antigen (HLA) complex, specifically classified as a class II molecule, and is encoded by genes located on chromosome 6. It plays a crucial role in the immune system by presenting peptide antigens to CD4+ T cells, which subsequently trigger adaptive immune responses, including the activation of B cells and the production of antibodies. HLA-DR is primarily expressed on antigen-presenting cells such as macrophages, dendritic cells, and B cells, and its expression levels can indicate the degree of immune system activation. This molecule is also significant in clinical settings, as it is associated with various autoimmune diseases (e.g., rheumatoid arthritis linked to HLA-DR4) and is a key factor in determining the success of organ transplants. Additionally, HLA-DR has been studied in the context of cancer immunotherapy, where its expression on tumor cells can influence the effectiveness of immune-mediated tumor suppression.
Flow cytometric analysis of Human HLA-DR expression on human PBMC (human peripheral blood mononuclear cells). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD19 antibody and either PE-Cy7 Mouse IgG2a Isotype Control (Left panel) or SDT PE-Cy7 Mouse Anti-Human HLA-DR Antibody (Right panel) at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
您现在的位置：